The Korean Organ Transplant Registry (KOTRY): Third Official Adult Heart Transplant Report
- Author:
Hyo-In CHOI
1
;
Sang Eun LEE
;
Junho HYUN
;
Darae KIM
;
Dong-Ju CHOI
;
Eun-Seok JEON
;
Hae-Young LEE
;
Hyun-Jai CHO
;
Hyungseop KIM
;
In-Cheol KIM
;
Jaewon OH
;
Minjae YOON
;
Jin Joo PARK
;
Jin-Oh CHOI
;
Min Ho JU
;
Seok-Min KANG
;
Soo Yong LEE
;
Sung-Ho JUNG
;
Jae-Joong KIM
Author Information
- Publication Type:Original Research
- From:Korean Circulation Journal 2025;55(2):79-96
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background and Objectives:The Korean Organ Transplant Registry (KOTRY) provided data for this third official report on adult heart transplantation (HT), including information from 709 recipients.
Methods:Data from HTs performed at seven major centers in Korea between March 2014 and December 2020 were analyzed, focusing on immunosuppression, acute rejection, cardiac allograft vasculopathy (CAV), post-transplant survival, and mechanical circulatory support (MCS) usage.
Results:The median ages of the recipients and donors were 56.0 and 43.0 years, respectively.Cardiomyopathy and ischemic heart disease were the most common preceding conditions for HT. A significant portion of patients underwent HT at waiting list status 1 and 0. In the multivariate analysis, a predicted heart mass mismatch was associated with a higher risk of 1-year mortality. Patients over 70 years old had a significantly increased risk of 6-year mortality. The risk of CAV was higher for male donors and donors older than 45 years. Acute rejection was more likely in patients with panel reactive antibody levels above 80%, while statin use was associated with a reduced risk. The employment of left ventricular assist device as a bridge to transplantation increased from 2.17% to 22.4%. Pre-transplant extra-corporeal membrane oxygenation was associated with worse post-transplant survival.
Conclusions:In this third KOTRY report, we analyzed changes in the characteristics of adult HT recipients and donors and their impact on post-transplant outcomes. The most notable discovery was the increased use of MCS before HT and their impact on post-transplant outcomes.
